Clinical Trial Update: Two-Year Study of the Safety and Efficacy of the Second-Generation Tissue Engineered Vascular Grafts [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study assessing safety and efficacy of a second-generation tissue engineered vascular graft for congenital heart …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Defects
• Double Inlet Left Ventricle
• Double Outlet Right Ventricle
• Hypoplastic Left Heart Syndrome
• Mitral Atresia
• Single Ventricle
• Tricuspid Atresia
• Unbalanced Atrioventricular Canal

Drugs mentioned

• Second-Generation Tissue Engineered Vascular Grafts

Snippet

Sponsor: Nationwide Children's Hospital | Conditions: HLH - Hypoplastic Left Heart Syndrome, DORV | Phase 2 | Status: RECRUITING